Results 191 to 200 of about 232,812 (303)

Plasmablastic Richter Transformation of Chronic Lymphocytic Leukemia With Aberrant Epithelial Marker Expression Presenting as a Pleural Effusion: A Diagnostic Challenge. [PDF]

Case Rep Pathol
Rogers J, Akhter JZ, Rosa M, Niyazi S, Werner-Idiaquez D, Pinilla-Ibarz J, Grajales-Cruz A, Moscinski L, Ryder CB.   +8 more
europepmc   +1 more source

Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry. [PDF]

Blood Cancer Discov
Maclachlan KH, Papadimitriou M, Blaney P, Baughn LB, Shekarkhand T, Poos AM, Ziccheddu B, Tang H, Yan H, Diamond B, Zhang Y, Cimera R, Dogan A, Gagler D, Boyle E, Hultcrantz M, Mailankody S, Hassoun H, Shah UA, Tan C, Brown EE, Winterkorn L, Chu T, Steinsnyder Z, Vaksman Z, Davies FE, Korde N, Landgren O, Raab MS, Lesokhin AM, Robine N, Weinhold N, Usmani SZ, Maura F, Morgan GJ.   +34 more
europepmc   +1 more source

A view from the periphery: trial design, commercial competition, and the access gap in multiple myeloma. [PDF]

Oncologist
Baysal M, Akpınar S.
europepmc   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

Extracorporeal Free-Light-Chain Removal in Myeloma Cast Nephropathy: Plasma Exchange and Hemodialysis Strategies in the Era of Effective Antimyeloma Therapy. [PDF]

J Clin Med
Gembillo G, Soraci L, Lo Cicero L, Terzo C, Casuscelli C, Cuzzola F, Sudano F, Ricca MF, Scapellato M, Messina R, La Spada A, Sharma A, Santoro D.   +12 more
europepmc   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Laryngeal amyloidosis: a single-centre four-patient case series highlighting diagnostic challenges and clinical heterogeneity. [PDF]

J Surg Case Rep
Ellan Govan RR, Sathish Kumar A, Rahmaan A, Youssef A, Manickavasagam JJ.   +4 more
europepmc   +1 more source

Clinical trials portfolio and regulatory outcomes of ixazomib in multiple myeloma: A systematic review and meta‐analysis

British Journal of Haematology, EarlyView.
Veer Shah, Darshi Shah, Payton Utzman, Karan Shah, Srivatsan Swaminathan, Maria Mainou, Rajshekhar Chakraborty, Aaron Goodman, Samer Al Hadidi, Amar H. Kelkar, Edward R. Scheffer Cliff, Ghulam Rehman Mohyuddin   +11 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Recurrent Epistaxis as a Rare Presentation of Extramedullary Multiple Myeloma. [PDF]

Cureus
Kumar V, Paswan V, Kumar P, Bhargava R.
europepmc   +1 more source